|

Afatinib plus chemotherapy as conversion treatment Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Shandong Public Health Clinical Center1

Indications

  • Carcinoma, Non-Small-Cell Lung1
  • Lung Cancer1
  • Cancer1

Other1 trial

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.